Sumitomo Pharma (Suzhou) Co., Ltd.
15
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
3 terminated/withdrawn out of 15 trials
78.6%
-7.9% vs industry average
80%
12 trials in Phase 3/4
45%
5 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
Role: collaborator
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Role: lead
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
Role: lead
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
Role: lead
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
Role: lead
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
Role: lead
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder
Role: lead
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
Role: lead
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
Role: lead
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
Role: lead
Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
Role: lead
A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
Role: lead
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
Role: lead
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
Role: collaborator
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Role: lead
All 15 trials loaded